Overview

The Repatriation Medical Authority Instrument No. 60 of 2010, under the Veterans’ Entitlements Act 1986, is an amendment to Statement of Principles Instrument No. 36 of 2009 concerning fibrosing interstitial lung disease. This legislative instrument was introduced to address a gap in the existing policy regarding veterans' health conditions, specifically focusing on revising factor 6(dd) related to 'paraquat poisoning'. The Repatriation Medical Authority, exercising its powers under the Act, undertook an investigation into the condition and, following the process outlined in the Legislative Instruments Act 2003, finalised the amendment. This Instrument also sets a specific date of effect for the amendment, ensuring clarity and effective implementation. The Authority advertised its intention to investigate and invited submissions from relevant stakeholders, although no submissions were received during the investigation. This Instrument aims to provide a comprehensive and updated understanding of the condition to assist in the assessment and compensation of affected veterans.

Scope and Application

This Instrument, under the Veterans’ Entitlements Act 1986, represents a significant development in the provision of healthcare and compensation to veterans affected by fibrosing interstitial lung disease, particularly in relation to paraquat poisoning. The Repatriation Medical Authority, exercising its powers under the Act, has amended Statement of Principles Instrument No. 36 of 2009, thereby refining the criteria for recognising and compensating veterans suffering from this condition. This legislative action applies to all veterans who may have been exposed to paraquat, a herbicide known for its severe respiratory effects, and who are consequently afflicted with fibrosing interstitial lung disease. The instrument ensures that veterans and their representatives can access detailed references supporting the revised medical understanding of the condition, thus aiding in claims and appeals processes. The geographic reach of this legislation is primarily federal, governed by the Commonwealth, but its implications extend to all states and territories where affected veterans reside. This legislative amendment is effective as of the date specified in accordance with the Legislative Instruments Act 2003, and it does not introduce any exclusions or exemptions beyond those already outlined in the relevant Acts.

Key Provisions

The main operative sections of this legislation (Instrument No. 60 of 2010) pertain to the amendments made to Statement of Principles Instrument No. 36 of 2009 concerning fibrosing interstitial lung disease. This amendment, as detailed in section 2 of the explanatory notes, revises factor 6(dd) which concerns ‘paraquat poisoning’. By making this revision, the legislation seeks to provide a more accurate and comprehensive understanding of the conditions under which veterans may be entitled to benefits related to fibrosing interstitial lung disease. Section 3 of the notes indicates that this Instrument specifies a date of effect in accordance with subsection 12(1)(a) of the Legislative Instruments Act 2003, ensuring that the changes are implemented from a specific date. The Repatriation Medical Authority, as the governing body, has certain obligations and requirements under this Act. Firstly, as per section 4, the Authority advertised its intention to investigate fibrosing interstitial lung disease in the Government Notices Gazette of 4 November 2009 and circulated a notice to relevant organisations and individuals. This was done to invite submissions from the Repatriation Commission, organisations, persons, and experts who have knowledge in the field. The Authority also ensured that any request for a list of references relating to the condition could be made in writing to the Repatriation Medical Authority Secretariat, as detailed in section 6. In terms of consequences and penalties for breach, the legislation does not explicitly state any civil or criminal penalties for non-compliance with its provisions. However, the seriousness of the amendments suggests that adherence to these updated principles is crucial for the proper administration of veterans' benefits. The Authority's role in determining and implementing these changes underscores the importance of accuracy and fairness in the assessment and provision of entitlements to affected veterans. Any failure to comply with these legislative requirements could potentially lead to disputes and legal challenges regarding the entitlements and benefits due to veterans suffering from fibrosing interstitial lung disease.